Phosphatidylinositol 3-Kinase (PI3K) Inhibitors Pipeline to Witness Increased R&D Investment in the Coming Years : P&S Market Research
PI3K inhibitors currently exhibits a strong pipeline with approximately 37 drug candidates.
September 4, 2017 /MarketersMedia/ —
According to a new research report “Phosphatidylinositol 3-Kinase (PI3K) Inhibitors Pipeline Analysis, 2017 – Clinical Trials & Results, Patent, Designation, Collaboration and Other Developments” published by P&S Market Research, PI3K inhibitors currently exhibits a strong pipeline with approximately 37 drug candidates.
Explore Report Description at: https://www.psmarketresearch.com/market-analysis/phosphoinositide-3-kinase-inhibitor-pipeline-analysis
Phosphatidylinositol 3-kinases (PI3K) are lipid kinases that are involved in cell regulation, including cell survival, proliferation and differentiation. They act as intermediate molecules in PI3K/AKT/mTOR signaling pathway by sending chemical messengers from cell surface to cytoplasm. These signals activate multiple effector kinase pathways, resulting in survival and growth of normal cells. Phosphatidylinositol 3-kinases is categorized on the basis of classes as class I, II and III, on the basis of structure of the PI3K, based on the specificities of the substrate as well as on the basis of lipid end-product’s nature. Bases on structure, Phosphatidylinositol 3-kinases has four different forms PI3K alpha, PI3K beta, PI3K gamma and PI3K delta.
In March 2017, Bayer AG presented clinical results of Phosphoinositide 3-kinase (PI3K)-targeting drug candidate Copanlisib in Phase II CHRONOS-1 trial, evaluating patients with relapsed or refractory indolent non-Hodgkin’s lymphoma (iNHL), trial with NCT ID 01660451. The results across all patient groups showed an objective response rate (ORR) of 59.2%, with a 12% complete response (CR) rate and a median duration of response (DOR) of more than 98 weeks, or 687 days (range 0-687).
Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/phosphoinositide-3-kinase-inhibitor-pipeline-analysis/report-sample
The major players for PI3K inhibitors pipeline include, but are not limited to, Novartis AG, Genentech, Inc., SignalRX Pharmaceuticals Inc. and others.
Contact Info:
Name: Abhishek
Email: enquiry@psmarketresearch.com
Organization: P&S Market Research
Address: 347, 5th Ave. #1402, New York City, NY – 10016
Phone: +1-888-778-7886
For more information, please visit https://www.psmarketresearch.com
Source: MarketersMedia
Release ID: 236081
Copyright © 1999-2013 SproutNews.com
